We have not explained this story yet. The original headline, summary and link are below.

BioCryst Pharmaceuticals has appointed a seven-member Scientific Advisory Board to guide its rare-disease research and development strategy, formalizing a shift towards external innovation. The company reported strong Q2 2026 revenues of USD 218.25 million and raised its full-year revenue guidance. Analysts maintain a "Moderate Buy" consensus with an average 12-month price target significantly above its current Nasdaq closing price.